These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 36701008)

  • 1. Clinical, cognitive, and morphometric profiles of progressive supranuclear palsy phenotypes.
    Campagnolo M; Weis L; Fogliano C; Cianci V; Garon M; Fiorenzato E; Carecchio M; Ferreri F; Bisiacchi P; Antonini A; Biundo R
    J Neural Transm (Vienna); 2023 Feb; 130(2):97-109. PubMed ID: 36701008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Motor, cognitive and behavioral differences in MDS PSP phenotypes.
    Picillo M; Cuoco S; Tepedino MF; Cappiello A; Volpe G; Erro R; Santangelo G; Pellecchia MT; Barone P;
    J Neurol; 2019 Jul; 266(7):1727-1735. PubMed ID: 30989369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes.
    Horta-Barba A; Pagonabarraga J; Martínez-Horta S; Busteed L; Pascual-Sedano B; Illán-Gala I; Marin-Lahoz J; Aracil-Bolaños I; Pérez-Pérez J; Sampedro F; Bejr-Kasem H; Kulisevsky J
    J Neurol; 2021 Sep; 268(9):3400-3408. PubMed ID: 33704556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic Spectrum of Progressive Supranuclear Palsy: Clinical Study and Apolipoprotein E Effect.
    Nasri A; Sghaier I; Neji A; Gharbi A; Abida Y; Mrabet S; Gargouri A; Djebara MB; Kacem I; Gouider R
    J Mov Disord; 2024 Apr; 17(2):158-170. PubMed ID: 38290492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism.
    Williams DR; de Silva R; Paviour DC; Pittman A; Watt HC; Kilford L; Holton JL; Revesz T; Lees AJ
    Brain; 2005 Jun; 128(Pt 6):1247-58. PubMed ID: 15788542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyramidal system involvement in progressive supranuclear palsy - a clinicopathological correlation.
    Stejskalova Z; Rohan Z; Rusina R; Tesar A; Kukal J; Kovacs GG; Bartos A; Matej R
    BMC Neurol; 2019 Mar; 19(1):42. PubMed ID: 30894142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uncovering clinical and radiological asymmetry in progressive supranuclear palsy-Richardson's syndrome.
    Picillo M; Tepedino MF; Abate F; Ponticorvo S; Erro R; Cuoco S; Oksuz N; Di Salle G; Di Salle F; Esposito F; Pellecchia MT; Manara R; Barone P
    Neurol Sci; 2022 Jun; 43(6):3677-3682. PubMed ID: 35106692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study.
    Nigro S; Antonini A; Vaillancourt DE; Seppi K; Ceravolo R; Strafella AP; Augimeri A; Quattrone A; Morelli M; Weis L; Fiorenzato E; Biundo R; Burciu RG; Krismer F; McFarland NR; Mueller C; Gizewski ER; Cosottini M; Del Prete E; Mazzucchi S; Quattrone A
    Mov Disord; 2020 Jun; 35(6):976-983. PubMed ID: 32092195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease.
    Zanigni S; Calandra-Buonaura G; Manners DN; Testa C; Gibertoni D; Evangelisti S; Sambati L; Guarino M; De Massis P; Gramegna LL; Bianchini C; Rucci P; Cortelli P; Lodi R; Tonon C
    Neuroimage Clin; 2016; 11():736-742. PubMed ID: 27330973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of PSP phenotypes with survival: A brain-bank study.
    Guasp M; Molina-Porcel L; Painous C; Caballol N; Camara A; Perez-Soriano A; Sánchez-Gómez A; Garrido A; Muñoz E; Marti MJ; Valldeoriola F; Grau O; Gelpí E; Respondek G; Höglinger GH; Compta Y
    Parkinsonism Relat Disord; 2021 Mar; 84():77-81. PubMed ID: 33581485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midbrain MRI assessments in progressive supranuclear palsy subtypes.
    Picillo M; Tepedino MF; Abate F; Erro R; Ponticorvo S; Tartaglione S; Volpe G; Frosini D; Cecchi P; Cosottini M; Ceravolo R; Esposito F; Pellecchia MT; Barone P; Manara R
    J Neurol Neurosurg Psychiatry; 2020 Jan; 91(1):98-103. PubMed ID: 31527182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Characterization of Cognitive Function in Typical and 'Brainstem Predominant'Progressive Supranuclear Palsy Phenotypes.
    Lee YC; Williams DR; Anderson JFI
    J Mov Disord; 2018 May; 11(2):72-77. PubMed ID: 29860785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants.
    Whitwell JL; Tosakulwong N; Botha H; Ali F; Clark HM; Duffy JR; Utianski RL; Stevens CA; Weigand SD; Schwarz CG; Senjem ML; Jack CR; Lowe VJ; Ahlskog JE; Dickson DW; Josephs KA
    Neuroimage Clin; 2020; 25():102152. PubMed ID: 31935638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which ante mortem clinical features predict progressive supranuclear palsy pathology?
    Respondek G; Kurz C; Arzberger T; Compta Y; Englund E; Ferguson LW; Gelpi E; Giese A; Irwin DJ; Meissner WG; Nilsson C; Pantelyat A; Rajput A; van Swieten JC; Troakes C; Josephs KA; Lang AE; Mollenhauer B; Müller U; Whitwell JL; Antonini A; Bhatia KP; Bordelon Y; Corvol JC; Colosimo C; Dodel R; Grossman M; Kassubek J; Krismer F; Levin J; Lorenzl S; Morris H; Nestor P; Oertel WH; Rabinovici GD; Rowe JB; van Eimeren T; Wenning GK; Boxer A; Golbe LI; Litvan I; Stamelou M; Höglinger GU;
    Mov Disord; 2017 Jul; 32(7):995-1005. PubMed ID: 28500752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease.
    Pellicano C; Assogna F; Cellupica N; Piras F; Pierantozzi M; Stefani A; Cerroni R; Mercuri B; Caltagirone C; Pontieri FE; Spalletta G
    Parkinsonism Relat Disord; 2017 Dec; 45():50-56. PubMed ID: 29037499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights from a multi-ethnic Asian progressive supranuclear palsy cohort.
    Lim SY; Dy Closas AMF; Tan AH; Lim JL; Tan YJ; Vijayanathan Y; Tay YW; Abdul Khalid RB; Ng WK; Kanesalingam R; Martinez-Martin P; Ahmad Annuar A; Lit LC; Foo JN; Lim WK; Ng ASL; Tan EK
    Parkinsonism Relat Disord; 2023 Mar; 108():105296. PubMed ID: 36682278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome.
    Ahn JH; Kim M; Kim JS; Youn J; Jang W; Oh E; Lee PH; Koh SB; Ahn TB; Cho JW
    Parkinsonism Relat Disord; 2019 Sep; 66():80-86. PubMed ID: 31307918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome.
    Williams DR; Holton JL; Strand C; Pittman A; de Silva R; Lees AJ; Revesz T
    Brain; 2007 Jun; 130(Pt 6):1566-76. PubMed ID: 17525140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy.
    Grijalva RM; Pham NTT; Huang Q; Martin PR; Ali F; Clark HM; Duffy JR; Utianski RL; Botha H; Machulda MM; Weigand SD; Ahlskog JE; Dickson DW; Josephs KA; Whitwell JL
    Mov Disord; 2022 Apr; 37(4):702-712. PubMed ID: 34970796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gait Analysis in Progressive Supranuclear Palsy Phenotypes.
    Picillo M; Ricciardi C; Tepedino MF; Abate F; Cuoco S; Carotenuto I; Erro R; Ricciardelli G; Russo M; Cesarelli M; Barone P; Amboni M
    Front Neurol; 2021; 12():674495. PubMed ID: 34177779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.